Last reviewed · How we verify

Shanghai Mental Health Center — Portfolio Competitive Intelligence Brief

Shanghai Mental Health Center pipeline: 12 marketed, 0 filed, 12 Phase 3, 12 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

12 marketed 0 filed 12 Phase 3 12 Phase 2 6 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
amisulpride with Clozapine amisulpride with Clozapine marketed
Perospirone hydrochloride tablets Perospirone hydrochloride tablets marketed Atypical antipsychotic Dopamine D2 receptor; Serotonin 5-HT2A receptor Psychiatry/Neurology
Placebo plus Lithium Placebo plus Lithium marketed Mood stabilizer GSK-3 (glycogen synthase kinase-3), inositol monophosphatase Psychiatry
fluoxetine + Amfebutamone fluoxetine + Amfebutamone marketed SSRI + NDRI combination antidepressant Serotonin transporter (SERT), norepinephrine transporter (NET), dopamine transporter (DAT) Psychiatry / Mental Health
Lithium carbonate + perospirone hydrochloride Lithium carbonate + perospirone hydrochloride marketed Mood stabilizer + atypical antipsychotic combination Inositol monophosphatase, GSK-3 (lithium); dopamine D2 receptor, serotonin 5-HT2A receptor (perospirone) Psychiatry
placebo with Clozapine placebo with Clozapine marketed Atypical antipsychotic Dopamine D2 receptor, Serotonin 5-HT2A receptor Psychiatry
toludesvenlafaxine hydrochloride sustained-release tablets toludesvenlafaxine hydrochloride sustained-release tablets marketed Serotonin-norepinephrine reuptake inhibitor (SNRI) Serotonin transporter (SERT) and norepinephrine transporter (NET) Psychiatry / Mental Health
Donepezil and Lithium Donepezil and Lithium marketed Cholinesterase inhibitor + mood stabilizer Acetylcholinesterase; GSK-3 and intracellular signaling pathways Neurology/Psychiatry
Lithium Carbonate Pill Lithium Carbonate Pill marketed Mood stabilizer Glycogen synthase kinase-3 (GSK-3), inositol monophosphatase Psychiatry
Mirtazapine/SNRIs Mirtazapine/SNRIs marketed Tetracyclic antidepressant Alpha-2 adrenergic receptors, 5-HT2 receptors, 5-HT3 receptors Psychiatry/Mental Health
Lithium+fluvoxamine Lithium+fluvoxamine marketed Mood stabilizer + SSRI combination Lithium: inositol monophosphatase and GSK-3β; Fluvoxamine: serotonin transporter (SERT) Psychiatry
sodium valproate with Clozapine sodium valproate with Clozapine marketed Antipsychotic + mood stabilizer combination Dopamine D2 receptor, serotonin 5-HT2A receptor, GABA pathways, histone deacetylase Psychiatry

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 3 shared drug classes
  2. New York State Psychiatric Institute · 2 shared drug classes
  3. Acacia Pharma Ltd · 2 shared drug classes
  4. Eli Lilly and Company · 2 shared drug classes
  5. Massachusetts General Hospital · 2 shared drug classes
  6. Ministry of Health & Welfare, Korea · 2 shared drug classes
  7. H. Lundbeck A/S · 2 shared drug classes
  8. University of North Carolina, Chapel Hill · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Shanghai Mental Health Center:

Cite this brief

Drug Landscape (2026). Shanghai Mental Health Center — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shanghai-mental-health-center. Accessed 2026-05-17.

Related